By Victor Legrand, Drug Market Consultant – Eurasia Business News, December 26, 2024. Article n°1350.
From january to october 2024, Russians spent 5.9 billion rubles ($ 59 million) on the purchase of more than 1 million packs of domestic generics of the drug ozempic (international nonproprietary name – semaglutide), according to the statistics of DSM Group.
We are talking about semavik medicines from Geropharm and Quincent from Promomed. Both are Russian pharmaceutical companies. The original drug ozempic has not been officially supplied to Russia since December 2023. Danish Novo Nordisk has stopped supplying Ozempik, used for diabetes mellitus and weight loss.
For comparison: in January-October 2023, Russian pharmacies earned 297 million rubles on the sale of 20,174 packs of ozempik, according to DSM Group data. For the same period in 2022, consumers spent 1.9 billion (256,493 packages were sold), in 2021 – 758 million rubles, in 2020 – 76 million rubles.
In early December Promomed, launched the sales of Velgia, a new generation Russian drug for the treatment of overweight and obesity (INN semaglutide). The first batches of the drug have already arrived at pharmacies in Russia. This new Russian drug is aimed primarily at overweight and obese patients. The drug significantly reduces weight, and also helps to correct disorders underlying cardiovascular and oncological diseases – the main causes of death in Russia.
In October 2023, Russian producer Promomed was granted a registration certificate for the glucose-lowering drug semaglutide, which is the active ingredient in Novo Nordisk’s Ozempic (for the treatment of patients with type 2 diabetes mellitus), and Wegovi (for obesity). The production of this Russian equivalent of semaglutide is done in the Promomed factory in the city of Saransk.
Our community already has nearly 145,000 readers!
Subscribe to our Telegram channel
Follow us on Telegram, Facebook and Twitter
© Copyright 2024 – Eurasia Business News. Article no. 1350.
Eurasia Business News 